Expanding Immunotheapy Benefit in Metastatic RCC

A Journal of Clinical Oncology podcast by Brian I. Rini, MD
Originally published Jan. 11, 2016

Discussion of a phase I trial of the checkpoint inhibitor atezolizumab in metastatic renal carcinoma.

Read the associated abstract by McDermott, et al: http://jco.ascopubs.org/lookup/doi/10.1200/JCO.2015.63.7421

Subscribe for more podcasts from JCO and JOP, and updates from ASCO
Learn more about the Journal of Clinical Oncology: http://jco.ascopubs.org/